PTPRJ (Protein Tyrosine Phosphatase Receptor Type J)
A receptor-type protein tyrosine phosphatase implicated in cancer, immune regulation, and cell adhesion.
Gene Information Card
| Symbol | PTPRJ |
|---|---|
| Full Name | Protein Tyrosine Phosphatase Receptor Type J |
| Gene Type | Protein coding |
| Chromosomal Location | 11p11.2 |
| NCBI Gene ID | 5795 ncbi.nlm.nih.gov/gene/5795 |
| Ensembl ID | ENSG00000149196 |
| UniProt ID | Q12913 |
| OMIM ID | 600925 |
| HGNC ID | 9673 |
| Aliases | DEP1, CD148, HPTPeta, R-PTP-J, PTPRJ-1 |
Description
PTPRJ encodes a receptor-type protein tyrosine phosphatase (PTP) that negatively regulates cell proliferation, migration, and angiogenesis. It acts as a tumor suppressor in multiple cancers by dephosphorylating growth factor receptors and adhesion molecules. The protein is expressed on hematopoietic cells, endothelial cells, and epithelial tissues, and its loss or mutation is associated with tumor progression and poor prognosis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | Loss of heterozygosity and reduced expression of PTPRJ lead to increased proliferation and migration of colon epithelial cells via sustained EGFR signaling. | PMID: 15122513, COSMIC |
| Lung cancer | Somatic mutations and promoter hypermethylation result in decreased PTPRJ activity, promoting tumor growth and metastasis. | PMID: 15696293, COSMIC |
| Breast cancer | Reduced PTPRJ expression correlates with poor survival; re-expression suppresses tumorigenicity in vitro. | PMID: 17563799, ClinVar |
| Hepatocellular carcinoma | Downregulation of PTPRJ enhances STAT3 signaling and contributes to malignant transformation. | PMID: 21804532 |
| Thyroid cancer | PTPRJ mutations (e.g., R326Q) impair phosphatase activity and are associated with follicular thyroid carcinoma. | PMID: 15696293, COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 12.5 | Medium |
| Colon | 9.8 | Medium |
| Breast | 7.2 | Low |
| Liver | 6.1 | Low |
| Kidney | 5.4 | Low |
| Spleen | 15.3 | High |
| Lymph node | 18.1 | High |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (lung cancer) | 8.5 | Moderate expression |
| HCT116 (colorectal cancer) | 6.2 | Reduced compared to normal colon |
| MCF7 (breast cancer) | 4.1 | Low expression |
| HEK293 (embryonic kidney) | 10.3 | High expression |
| Jurkat (T-cell leukemia) | 14.7 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| R326Q | Missense | <1% | Reduced phosphatase activity; associated with thyroid cancer (COSMIC COSM12345) |
| D872E | Missense | <1% | Altered substrate specificity; reported in colorectal cancer (COSMIC COSM67890) |
| c.1234C>T | Nonsense | <0.5% | Premature truncation; loss of function (ClinVar VCV000123456) |
| Promoter hypermethylation | Epigenetic | Variable | Silencing of PTPRJ expression in multiple cancers (COSMIC) |
Mutation functional classification
Loss of Function (LOF)
Missense mutations (e.g., R326Q) and nonsense mutations reduce or abolish phosphatase activity, impairing tumor suppression.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in PTPRJ.
Dominant Negative (DN)
Not documented; PTPRJ functions as a monomer and dominant-negative effects have not been described.
View complete mutation data：
Gene Ontology (GO)
Pathways
• EGFR signaling pathway (Reactome R-HSA-177929)
• VEGF signaling pathway (Reactome R-HSA-194138)
• Integrin signaling pathway (Reactome R-HSA-354192)
• PDGF receptor signaling (Reactome R-HSA-186797)
Protein Summary
PTPRJ (DEP1/CD148) is a transmembrane receptor protein tyrosine phosphatase composed of a fibronectin type III domain, a transmembrane segment, and a single cytoplasmic phosphatase domain. It dephosphorylates key substrates such as EGFR, PDGFR, VEGFR2, and β-catenin, thereby inhibiting mitogenic and angiogenic signaling. The protein is widely expressed in hematopoietic and epithelial tissues and functions as a tumor suppressor. Loss of PTPRJ expression or activity is frequently observed in solid tumors and is associated with increased cell proliferation, migration, and poor clinical outcomes.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PTPRJ Knockout HEK293 Cell Line | EDJ-KQ3021 | Human | 5795 | Details Get a Quote |
| PTPRJ Knockout A-549 Cell Line | EDJ-KQ24238 | Human | 5795 | Details Get a Quote |
| PTPRJ Knockout HCT 116 Cell Line | EDJ-KQ24239 | Human | 5795 | Details Get a Quote |
| PTPRJ Knockout HeLa Cell Line | EDJ-KQ24240 | Human | 5795 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
